Galectovid is available ove -the-cou te (OTC) without a p esc iptio at pa t e Tollo Health’s o li e sto e www.TolloHealth.Shop a d at the Compa y’s wholly-ow ed pha macy Co exa Pha macy’s o li e sto e http://www.co exa x.com/Sto e The effects of Galectovid a e expected to begi withi hou s. Galectovid is catego ized as a medical food u de sectio 5(b)(3) of the O pha D ug Act (21 U.S.C. 360ee(b)(3)), with each of its i g edie ts o the U.S. Food & D ug Admi ist atio ‘s Ge e ally Recog ized as Safe (GRAS) list. Medical Foods like Galectovid a e mea t to be take u de the supe visio of a physicia .
Detailed Galectovid mecha ism of actio video
“We believe that co sume s will be ext emely happy with Galectovid as thei ally th oughout the 2026 Cold & Flu Seaso ,” said Ge ald Commissio g, i te im co-CEO of DataMEDS. “We have begu expa di g ou Galectovid-focused acute i fectio esea ch activities th ough key, p e-established, t usted physicia elatio ships. We look fo wa d to updati g physicia s a d co sume s o the pote tial be efits of Galectovid as ew data becomes available.”
Fo mo e i fo matio o DataMeds AI, I c., efe to www.datamedsai.com
Galectovid is a medical food fo the dieta y ma ageme t of galecti -1 a d galecti -3 associated vi al i fectio s. Galectovid is fo mulated to i hibit galecti -1 a d galecti -3 p otei s, which a e associated with the immu e espo se to a d cellula e t y of va ious vi uses, i cludi g SARS-CoV-2, RSV, He pes Simplex Vi us-1, a d I flue za A. Galectovid’s i g edie ts a e Ge e ally Recog ized As Safe (GRAS) a d may be used alo gside othe atu al a tivi al p oducts as pa t of a b oade ma ageme t pla fo acute o ch o ic vi al i fectio s, i cludi g those associated with Lo g COVID.
To pu chase Galectovid, please visit www.TolloHealth.shop o www.Co exaRx.com/Sto e.
Tollo Health, LLC is a healthca e compa y developi g a d comme cializi g atu e-based the apeutics, i cludi g Tollovid a d Galcetovid, alo gside its Health Lives He e telehealth platfo m a d TolloBio biologics developme t p og ams. Co exa Health Pha macy, a subsidia y of DataMeds AI, I c., dist ibutes select Tollo Health p oducts u de a wholesale dist ibutio a a geme t.
DataMeds AI, I c. (fo me ly Wellgistics Health) is a leadi g Health IT compa y that focuses o the ve tical i teg atio of tech ology, pha macy, pha maceutical-adjace t a d telemedici e busi ess u its to delive a bette healthca e expe ie ce fo co sume s. Headqua te ed i Tampa, Fla., DataMeds AI i co po ates the a tificial i tellige ce platfo m Ei stei Rx™ a d blockchai -e abled sma t co t acts platfo m Pha macyChai ™ i to the Health Lives He e mobile applicatio , a d its Co exa Health subsidia y p ovides pha macy a d pha macy se vices, i cludi g the dist ibutio of p oducts developed by Tollo Health, LLC.
This p ess elease co tai s fo wa d-looki g stateme ts withi the mea i g of the P ivate Secu ities Litigatio Refo m Act of 1995. Fo wa d-looki g stateme ts i clude, without limitatio , stateme ts ega di g: futu e eve ts, i cludi g DataMeds AI, I c.’s payme t of the D eam Bowl Toke s a d the timi g the eof (i cludi g that the Boa d may cha ge the Payme t Date) a d the Compa y’s i te tio to delive liquidity a d b oad dist ibutio of the D eam Bowl Toke s. These stateme ts a e based o ma ageme t’s cu e t expectatio s a d a e ot p edictio s of actual pe fo ma ce.; the Compa y’s pla s to expa d i to telemedici e a d diag ostic labo ato y se vices; the Compa y’s p oposed t a sactio with DataVault AI I c., Scilex Holdi g Compa y, EOS Holdi gs a d HealthB idge Adviso s; the satisfactio o waive of closi g co ditio s applicable to a y of the fo egoi g; the eceipt of stockholde app oval a d a y othe equi ed app ovals; the Compa y’s a ticipated busi ess st ategy, ope ati g pla s a d g owth oppo tu ities; the i teg atio of telemedici e, pha macy, labo ato y, wea able-device, a tificial i tellige ce, blockchai a d data-ma ageme t tech ologies; the p oposed developme t, comme cializatio a d expa sio of Ei stei Rx AI, Pha macyChai , Health Lives He e a d elated platfo ms; the a ticipated g owth of the ma ket fo Lo g COVID p oducts a d elated t eatme t app oaches; the Compa y’s ability to empowe patie ts to access, ma age, co t ol o mo etize health data; the a ticipated be efits of the Compa y’s tech ology platfo ms, st ategic elatio ships a d busi ess combi atio s; the Compa y’s capitalizatio , outsta di g secu ities, lock-up a a geme ts, public float a d egist atio stateme ts; the Compa y’s ability to mai tai complia ce with Nasdaq listi g sta da ds; a d the Compa y’s liquidity, capital esou ces a d ability to fu d ope atio s.
Fo wa d-looki g stateme ts speak o ly as of the date of this p ess elease. The Compa y u de takes o obligatio to update o evise a y fo wa d-looki g stateme ts, whethe as a esult of ew i fo matio , futu e eve ts o othe wise, except as equi ed by law.
